Gluskin Sheff & Assoc Inc Regeneron Pharmaceuticals, Inc. Transaction History
Gluskin Sheff & Assoc Inc
- $739 Million
- Q1 2025
A detailed history of Gluskin Sheff & Assoc Inc transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Gluskin Sheff & Assoc Inc holds 1,469 shares of REGN stock, worth $747,515. This represents 0.13% of its overall portfolio holdings.
Number of Shares
1,469
Previous 2,219
33.8%
Holding current value
$747,515
Previous $1.58 Million
41.08%
% of portfolio
0.13%
Previous 0.2%
Shares
12 transactions
Others Institutions Holding REGN
# of Institutions
1,471Shares Held
85.8MCall Options Held
1.39MPut Options Held
1.45M-
Vanguard Group Inc Valley Forge, PA9.41MShares$4.79 Billion0.11% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$4.3 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY5.66MShares$2.88 Billion0.28% of portfolio
-
State Street Corp Boston, MA4.79MShares$2.44 Billion0.13% of portfolio
-
Capital International Investors Los Angeles, CA3.99MShares$2.03 Billion0.52% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $54.5B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...